New treatments for chronic urticaria
Chronic urticaria (CU) is a common, heterogeneous and debilitating disease. Antihistamines and omalizumab are the mainstay therapies of CU. Additional treatment options are needed. Here, we review the off and beyond label use of licensed drugs, novel treatments that are currently under development, and promising new targets.
Chronic spontaneous urticaria (CSU) is often associated with organ specific autoimmunity but is rarely caused by food allergy. Colourings and preservatives in pre-packaged foods, so called pseudoallergens, hav...
CONCLUSION: A similar approach to that used for peanut OIT can be taken for non-peanut foods, and for multiple foods simultaneously. High baseline allergy test results are not a contraindication to OIT. PMID: 31494236 [PubMed - as supplied by publisher]
CONCLUSION: The development of new treatments for CSU will importantly lead to improved options for patients and may assist with improving our understanding of disease pathophysiology. PMID: 31494233 [PubMed - as supplied by publisher]
To review the published literature on current and new treatments for chronic spontaneous urticaria (CSU) and to provide guidance on the potential use of these therapeutics.
Alpha-gal allergy is associated with immunoglobulin E (IgE) antibodies to galactose- α-1,3-galactose (alpha-gal), a carbohydrate found in beef, pork, and lamb. First described in the adult population in 2009 by Commins et al., this syndrome is associated with delayed anaphylaxis, angioedema, and urticaria with symptom onset 3 to 6 hours after eating red meat.1,2,3 Bites from ticks, namely the Lone Star Tick (Amblyomma americanum) in the United States, are associated with production of IgE antibodies to alpha-gal, resulting in an immune system primed to react to foods containing the antigen in patients who previously ...
Aspirin is first-line treatment in coronary artery disease (CAD) patients, but in patients with acute coronary syndrome (ACS) or who require dual antiplatelet therapy after myocardial revascularization, aspirin therapy becomes critical and time-sensitive1. Approximately 1.5% of CAD patients report aspirin allergy2. Most reactions are considered non-immunologic, related to aspirin ’s inhibition of cyclo-oxygenase causing allergic-like symptoms3. A subset of patients has aspirin exacerbated respiratory disease (AERD) or chronic idiopathic urticaria (CIU) exacerbated by aspirin.
Abstract OBJECTIVE: Chronic urticaria (CU) is a common, heterogeneous and debilitating disease. Antihistamines and omalizumab are the mainstay therapies of CU. Additional treatment options are needed. Here, we review the off and beyond label use of licensed drugs, novel treatments that are currently under development, and promising new targets. DATA SOURCES: and Study Selection: We performed a thorough search of the recent literature on reports of the successful use of treatments in CU and promising targets for the development of novel treatment options. Also, we searched clinicaltrials.gov for recent and ong...
This article was originally published on Undark. Read the original article.
Drug-induced hypersensitivity reactions are of major medical concern. Approximately 45% of all the adverse drug reactions are manifested in the skin, which occur in 2%-3% hospitalized patients upon drug administration1. Drug hypersensitivity reactions can be categorized into immediate reactions and delayed reactions. Immediate reactions occur within minutes or hours of drug exposure 2. The manifestations of immediate-type reactions range from pruritus, urticaria, angioedema to anaphylaxis. The delayed-type reactions are primarily T cell-mediated type IV reactions that usually takes several days or even weeks to manifest after drug exposure.